This announcement is a separate document:
四川百利天恒药业股份有限公司自愿披露关于BL-B01D1（EGFR×HER3-ADC）用于局部晚期或转移性EGFR野生型非小细胞肺癌III期临床试验完成首例受试者入组的公告
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed the announcement that BL-B01D1 (EGFR×HER3-ADC) for locally advanced or metastatic EGFR wild-type non-small cell lung cancer phase III clinical trial completed
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.